Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Karolinska Institutet | OTHER |
Not provided
Not provided
Not provided
Not provided
Chronic diseases such as cardiovascular disease and diabetes type 2 are major causes of death worldwide. Preventive interventions can be delivered through primary care, as this is the first-line healthcare with which a considerable proportion of the population comes into contact every year. The goal of this cluster-randomized trial is to compare the effects of a Health Dialogue Intervention (HDI) to Opportunistic Screening (OS) in primary care among middle-aged adults with low socioeconomic status. The main questions it aims to answer are:
DETECT (health Dialogue intErvention versus opporTunistic scrEening in primary Care for Type 2 diabetes and cardiovascular disease prevention) targets the challenges of primary prevention for individuals with low socioeconomic status by implementing and evaluating two preventive interventions, a Health Dialogue Intervention (HDI) and an Opportunistic Screening (OS), conducted in primary care, specifically targeting settings with low socioeconomic status. The interventions will focus on detecting risk factors for CVD and supporting changes in unhealthy lifestyle behaviors.
The study is designed as a parallel cluster-randomized trial with two conditions, with primary care centers (PCCs) serving as the unit of randomization and individual patients as units of observation for primary and secondary outcomes. Participants randomized to the HDI intervention will be invited to partake in a systematic screening of cardiovascular and metabolic risk factors using questionnaires, blood sampling, and clinical examinations, all of which together form the risk profile. Next, they will be invited to an individually oriented health dialogue which is prescribed by a care provider. The dialogue focuses on promoting healthy lifestyle behaviors and is based on the screening results and the given risk profile. The effects of HDI will be compared to that from OS, wherein participants will be recruited upon scheduling of an appointment at their PCC for any reason, except for individuals with pre-scheduled appointments related to hypertension, T2D, and CVD. Participants receiving OS will be screened for hypertension, overweight/obesity, tobacco usage, blood-lipid profile, and blood glucose.
Short-term outcomes will be assessed at baseline, and 6 and 12-months after receiving the intervention, and long-term outcomes (i.e. 5 and 10 years post intervention) using nationwide registers.
The goal is to recruit a total of 30 PCCs (n=15 in each arm) in the county of Stockholm. Based on real observed variance in levels of systolic blood pressure in the county of Stockholm and accounting for clustering effects, the investigators calculate that a minimum of 840 participants (n=420 in each arm and n=28 per cluster) would yield 80% power to detect a reduction of 5 mmHg systolic blood pressure in the HDI group. To allow for the expected difficulties with recruitment and subsequent attrition, the investigators therefore aim to recruit n=100 patients per cluster, yielding a total study population of 3000.
The core tool of analysis will be a hierarchical model consisting of two levels, individuals and PCCs. The primary model for analyzing changes in systolic blood pressure (primary outcome), other risk factors, lifestyle behaviors, and quality-of-life over 6 and 12 months, will be a mixed-effects Generalized Linear Model to capture variability between and within PCCs. In these models, the treatment effect (HDI versus OS) will be assessed using a fixed effect represented by a dummy variable at PCC level, specifying the type of treatment (HDI/OS). Together, this enables the estimation of the average treatment effect, while accounting for the hierarchical structure of the data. We will estimate unadjusted effects and effects adjusted both/either at the individual level and PCC level, e.g., adjusted for demographic characteristics, socioeconomic status, CNI level, and baseline values of the referred outcome. The analysis will be conducted on an intention-to-treat basis. Potential effect modification will be explored through subgroup analyses and interaction analyses considering sex, birth country, and socioeconomic characteristics. A sensitivity analysis will be conducted to assess whether the individual randomization of a single PCC introduced bias. Thus, we will perform analyzes both including and excluding this PCC.
For the assessment of T2D and CVD incidence and mortality during the extended 5 and 10 years of follow-up, we will calculate hazard ratios using a mixed-effect Cox regression. We will also calculate the number needed to treat (NNT) as 1/absolute risk reduction.
Finally, we also aim to estimate the time needed to treat (TNT) for the interventions. The TNT is a new method designed to consider clinician's time as a finite resource, with the aim of facilitating for guideline committees who develop clinical practice guidelines. The TNT can be expressed in three different ways: 1) the clinician time needed to improve the outcome for one person (TNTNNT), 2) the clinician time needed to provide the intervention for all eligible in a population (absolute TNT), 3) the proportion of the total clinician time available for patient care needed to implement the intervention for everyone eligible (relative TNT). More detailed information on the TNT method and its assumptions is available elsewhere.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Health Dialogue Intervention | Experimental |
| |
| Opportunistic Screening | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Health Dialogue Intervention | Behavioral |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in systolic blood pressure (mmHg) | Measured by care providers in accordance with routine guidelines | Baseline (defined as time of HDI/OS), 6 months post intervention, 12 months post intervention |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in blood cholesterol levels | Measured by care providers in accordance with routine guidelines | Baseline, 6 months post intervention, 12 months post intervention |
| Change in blood glucose levels | Measured by care providers in accordance with routine guidelines |
Inclusion Criteria:
Exclusion Criteria:
• None.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hanna Augustsson, PhD | Center for epidemiology and community medicine, Region Stockholm | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for epidemiology and community medicine, Region Stockholm | Stockholm | 10435 | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39394167 | Derived | Ballin M, Backman Enelius M, Dini S, Galanti MR, Hagstromer M, Heintz E, Lager A, de Leon AP, Lundh L, Nystrand C, Walldin C, Augustsson H. Health dialogue intervention versus opportunistic screening in primary care for type 2 diabetes and cardiovascular disease prevention in settings with low socioeconomic status (DETECT): study protocol for a pragmatic cluster-randomized trial. Trials. 2024 Oct 12;25(1):672. doi: 10.1186/s13063-024-08533-8. |
Not provided
Not provided
Individual participant data will not be shared in accordance with Swedish law and regulations.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Pragmatic, cluster-randomized trial
Not provided
Not provided
Not provided
|
| Opportunistic Screening | Other |
|
|
| Baseline, 6 months post intervention, 12 months post intervention |
| Change in body-mass-index | Measured by care providers in accordance with routine guidelines | Baseline, 6 months post intervention, 12 months post intervention |
| Change in quality-of-life | Measured by EQ-5D (EuroQol-5 Dimension). From the five dimensions, a summary index is derived, with a maximum score of 1, where 1 indicates the best health state. | Baseline, 6 months post intervention, 12 months post intervention |
| Change in tobacco usage | Measured by self-reported questionnaires | Baseline, 6 months post intervention, 12 months post intervention |
| Change in dietary habits | Measured by self-reported questionnaires | Baseline, 6 months post intervention, 12 months post intervention |
| Change in alcohol consumption | Measured by self-reported questionnaires | Baseline, 6 months post intervention, 12 months post intervention |
| Change in physical activity | Measured by self-reported questionnaires | Baseline, 6 months post intervention, 12 months post intervention |
| Incidence of ischemic heart disease | Collected from national registries | 5 and 10 years post intervention |
| Incidence of stroke | Collected from national registries | 5 and 10 years post intervention |
| Incidence of type 2 diabetes | Collected from national registries | 5 and 10 years post intervention |
| Mortality due to cardiovascular disease or type 2 diabetes | Collected from national registries | 5 and 10 years post intervention |
| Healthcare costs in the health dialogue group vs. the opportunistic screening group | Administrative data collected form health care providers | 12 months post intervention |
| Costs per attained blood pressure target among individuals in the health dialogue group vs. the opportunistic screening group | Administrative data collected form health care providers | 12 month post intervention |
| D004700 | Endocrine System Diseases |